The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study-Reference-Cited by-同舟云学术

The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study

Published:2020-05 Issue: Volume:130 Page:39-50
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Michot Jean-Marie,Lappara Ariane,Le Pavec Jérôme^ORCID,Simonaggio Audrey^ORCID,Collins Michael,De Martin Eléonora,Danlos François-Xavier,Ammari Samy,Cauquil Cécile,Ederhy Stéphane,Barreau Emmanuel,Belkhir Rakiba,Berdelou Amandine,Lazarovici Julien,Chanson Philippe,Izzedine Hassan,Seferian Andrei,Le Pajolec Christine,Baldini Capucine,Martin-Romano Patricia,Mariette Xavier,Robert Caroline,Besse Benjamin,Hollebecque Antoine,Varga Andrea,Laghouati Salim,Mateus Christine,Voisin Anne-Laure,Soria Jean-Charles,Massard Christophe,Marabelle Aurélien,Champiat Stéphane,Lambotte Olivier

Funder

Gustave Roussy

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade;Hirsch;Br J Canc,2019

3. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma;Weber;J Clin Oncol,2017

4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016

5. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Haanen;Ann Oncol Off J Eur Soc Med Oncol,2017

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gestion des toxicités des immunothérapies du cancer : challenges et « rechallenges » pour les (jeunes) internistes;La Revue de Médecine Interne;2024-01

2. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU;Revista Española de Enfermedades Digestivas;2024

3. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-01

4. Association between immune‐related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis;Fundamental & Clinical Pharmacology;2023-11-27

5. Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology;European Journal of Cancer;2023-11